ZD6126: A novel vascular-targeting agent that causes selective destruction of tumor vasculature

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7247-7253

  Davis, Peter D ^a   Dougherty, Graeme J ^a   Blakey, David C ^b   Galbraith, Susan M ^c   Tozer, Gillian M ^c   Holder, Angela L ^c   Naylor, Matthew A ^c   Nolan, John ^c   Stratford, Michael R L ^c   Chaplin, David J ^c   Hill, Sally A ^c  

^a Angiogene Pharmaceuticals Ltd   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (ACETYLAMINO) 9,10,11 TRIMETHOXY 6,7 DIHYDRO 5H DIBENZO[A,C]CYCLOHEPTEN 3 YL DIHYDROGENPHOSPHATE; ANGIOGENESIS INHIBITOR; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL; PRODRUG; TUBULIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG SYNTHESIS; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR VASCULARIZATION;

ADENOCARCINOMA; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, SQUAMOUS CELL; CATTLE; CELL SURVIVAL; COLCHICINE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED CBA; MICE, SCID; NECROSIS; NEOPLASMS, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPHOSPHORUS COMPOUNDS; PHARYNGEAL NEOPLASMS; PRODRUGS; PROTEIN BINDING; TUBULIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0037115398     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Folkman, J., Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
2. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
3. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
4. Strawn, L. M., McMahon, G., App, H., Schreck, R., Huchler, W. R., Longhi, M. P., Hui, T. H., Tang, C., Lebitzki, A., Gazit, A., Chen, I., Keri, G., Orfi, L., Risau, W., Flamme, I., Ulrich, A., Hirth, K. P., and Shawver, L. K. Flk-1 as a target for tumor growth inhibition. Cancer Res., 56: 3540-3545, 1996.
5. Chaplin, D. J., and Dougherty, G. J. Tumour vasculature as a target for cancer therapy. Br. J. Cancer, 80 (Suppl.): 57-64, 1999.
6. Hill, S. A., Lonergan, S. J., Denekamp, J., and Chaplin, D. J. Vinca alkaloids: Anti-vascular effects in a murine tumour. Eur. J. Cancer, 29A: 1320-1324, 1993.
7. Chaplin, D. J., Pettit, G. R., Parkins, C. S., and Hill, S. A. Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Br. J. Cancer, 74 (Suppl.): S86-S88, 1996.
8. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57: 1829-1834, 1997.
9. Watts, M. E., Woodcock, M., Arnold, S., and Chaplin, D. J. Effects of novel and conventional anti-cancer agents on human endothelial permeability: Influence of tumour secreted factors. Anticancer Res., 17: 71-75, 1997.
10. Tozer, G. M., Prise, V. E., Wilson, J., Cemazar, M., Shan, S., Dewhirst, M. W., Barber, P. R., Vojnovic, B., and Chaplin, D. J. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: Intravital microscopy and measurement of vascular permeability. Cancer Res., 61: 6413-6422, 2001.
11. Kang, G-J., Zalleka, G., Muzaffar, A., Brossi, A., and Hamel, E. N-acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring. J. Biol. Chem., 265: 10255-10259, 1990.
12. Cech, J., and Santavy, F. The effect of hydrogen peroxide in alkaline medium on colchiceine. Collect. Czech. Chem. Commun., 4: 532-539, 1949.
13. Jaffe, E. A., Nachman, R. L., Becker, C. G., and Minick, C. R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J. Clin. Invest., 52: 2745-2756, 1973.
14. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br. J. Cancer, 77: 1-10, 1998.
15. Burtles, S. S., Newell, D. R., Henrar, R. D., and Connors, T. A. Revision of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Res. Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) new drug development office. Eur. J. Cancer, 31A: 408-410, 1995.
16. Parkins, C. S., Hill, S. A., Lonergan, S. J., Horsman, M. R., Chadwick, J. A., and Chaplin, D. J. Ischaemia induced cell death in tumors: Importance of temperature and pH. Int. J. Radiat. Oncol. Biol. Phys., 29: 499-503, 1994.
17. Gotlieb, A. I., The endothelial cytoskeleton:Organization in normal and regenerating endothelium. Toxicol. Pathol., 18: 603-617, 1990.
18. Denekamp, J., Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev., 9: 267-282, 1990.
19. Berenstein, A., and Kricheff, I. Microembolization techniques of vascular occlusion: Radiologic, pathologic, and clinical correlation. Am. J. Neuroradiol., 2: 261-267, 1981.
20. Baguley, B. C., Holdaway, K. H., Thomsen, L. L., Zhuang, L., and Zwi L. J., Inhibition of growth of colon 38 adenocarcinomas by vinblastine and colchicines. Evidence for a vascular mechanism. Eur. J. Cancer, 27: 482-487, 1991.
21. Hill, S., Williams, K. B., and Denekamp, J. Vascular collapse after flavone acetic acid: A possible mechanism of its anti-tumour action. Eur. J. Cancer Clin. Oncol., 25: 1419-1424, 1989.
22. Murata, R., Overgaard, J., Horsman, M. R. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int. J. Radiat. Biol., 77: 195-204, 2001.
23. Sabouraud, A., Rochdi, M., Urtizberea, M., Christen, M. O., Achtert, G., and Scherrmann, J. M. Pharmacokinetics of colchicine: A review of experimental and clinical data. Z. Gastroenterol., 30 (Suppl.): 35-39, 1992.
24. van Tellingen, O., Sips, J. H., Beijnen, J. H., Bult, A., and Nooijen, W. J. Pharmacology, bio-analysis and pharmacokinetics of the Vinca alkaloids and semi-synthetic derivatives (review). Anticancer Res., 12: 1699-1715, 1992.
25. Eberhard, A., Kahlert, S., Goede, V., Hemmerlein, B., Plate, K. H., Augustin, H. G. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: Implications for antiangiogenic tumor therapies. Cancer Res., 60: 1388-1393, 2000.
26. Wong M. K., and Gotlieb, A. I. Endothelial cell monolayer integrity. I. Characterization of dense peripheral band of microfilaments. Arteriosclerosis, 6: 212-219, 1986.
27. Takeguchi, K., Kuroda, K., Ishigami, M., and Nakamura, T. Actin cytoskeleton of resting bovine platelets. Exp. Cell Res., 186: 374-380, 1990.
28. Zand, M. S., and Albrecht-Buehler, G., What structures, besides adhesions, prevent spread cells from rounding up? Cell Motil. Cytoskeleton, 13: 195-211, 1989.
29. Tozer, G. M., Prise, V. E., Wilson, J., Locke, R. J., Vojnovic, B., Stratford, M. R., Dennis, M. F., and Chaplin, D. J. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: Early effects in tumors and normal tissues. Cancer Res., 59: 1626-1634, 1999.
30. Boucher, Y., Baxter, L. T., and Jain, R. K., Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: Implications for therapy. Cancer Res., 50: 4478-4484, 1990.
31. Chaplin, D. J., Pettit, G. R., and Hill, S. A. Anti-vascular approaches to solid tumour therapy: Evaluation of combretastatin A-4 phosphate. Anticancer Res., 19: 189-195, 1999.
32. Grosios, K., Holwell, S. E., McGown, A. T., Pettit, G. R., and Bibby, M. C. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br. J. Cancer, 81: 1318-1327, 1999.